Edgen Stock·Sep 19 2025, 00:49戻る
戻る
FDA Grants Breakthrough Therapy Designation for Daiichi Sankyo and Merck's Raludotatug Deruxtecan
Edgen Stock·Sep 19 2025, 00:49
[1] Raludotatug Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab[2] MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer - Nasdaq[3] MRK, Daiichi's ADC Drug Gets FDA Breakthrough Tag for Ovarian Cancer - Zacks